BlackRock
TCRX icon

BlackRock’s TScan Therapeutics TCRX Stock Holding History

BlackRock’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$975K Sell
994,654
-846,298
-46% -$902K ﹤0.01% 4361
2026
Q1 		$1.86M Sell
1,840,952
-7,743
-0.4% -$8.27K ﹤0.01% 4146
2025
Q4 		$1.85M Sell
1,848,695
-534,069
-22% -$773K ﹤0.01% 4138
2025
Q3 		$4.34M Sell
2,382,764
-183,760
-7% -$325K ﹤0.01% 3838
2025
Q2 		$3.72M Sell
2,566,524
-2,312,309
-47% -$3.34M ﹤0.01% 3884
2025
Q1 		$6.73M Sell
4,878,833
-82,867
-2% -$179K ﹤0.01% 3509
2024
Q4 		$15.1M Buy
4,961,700
+328,824
+7% +$1.49M ﹤0.01% 3210
2024
Q3 		$23.1M Buy
4,632,876
+170,524
+4% +$1.03M ﹤0.01% 2941
2024
Q2 		$26.1M Buy
4,462,352
+2,763,139
+163% +$21.8M ﹤0.01% 2820
2024
Q1 		$13.5M Buy
1,699,213
+27,486
+2% +$173K ﹤0.01% 3192
2023
Q4 		$9.75M Sell
1,671,727
-8,722
-0.5% -$39.9K ﹤0.01% 3409
2023
Q3 		$4.3M Buy
1,680,449
+416,996
+33% +$973K ﹤0.01% 3710
2023
Q2 		$3.16M Sell
1,263,453
-251,597
-17% -$675K ﹤0.01% 3880
2023
Q1 		$3.18M Buy
1,515,050
+1,104
+0.1% +$2.62K ﹤0.01% 3836
2022
Q4 		$2.35M Buy
1,513,946
+131
+0% +$321 ﹤0.01% 4069
2022
Q3 		$4.62M Sell
1,513,815
-1,149
-0.1% -$3.76K ﹤0.01% 3791
2022
Q2 		$4.76M Sell
1,514,964
-4,224
-0.3% -$11.6K ﹤0.01% 3837
2022
Q1 		$4.25M Buy
1,519,188
+20,650
+1% +$89.3K ﹤0.01% 4053
2021
Q4 		$6.74M Sell
1,498,538
-2,039
-0.1% -$14.7K ﹤0.01% 3873
2021
Q3 		$12.5M Buy
+1,500,577
New +$13.9M ﹤0.01% 3574

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

BlackRock's TCRX Position: Q2 2026 in Review

BlackRock reduced its TScan Therapeutics (TCRX) stake by 46% in Q2 2026, selling an estimated $902K and leaving 994,654 shares worth $975K. The position accounts for ﹤0.01% of the portfolio, ranked #4361.

BlackRock first reported a position in TCRX in Q3 2021 and has held it in 20 quarters since. The position peaked at $26.1M in Q2 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • BlackRock held 994,654 shares of TScan Therapeutics worth $975K as of Q2 2026.
  • BlackRock sold 846,298 TScan Therapeutics shares in Q2 2026, an estimated $902K.
  • TScan Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4361 holding.
  • BlackRock first reported a position in TScan Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • BlackRock's TScan Therapeutics position peaked at $26.1M in Q2 2024.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.